.Attribute Medication, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of clients with HER2+ state-of-the-art bosom cancer cells as well as active or stable mind metastases revealed consistent intracranial task and also wide spread efficacy of T-DXd.